Definition Tyrosine kinase inhibitors ( TKIs ) are small molecules that bind to and inhibit the activity of tyrosine kinases. The latter are enzymes that catalyze the phosphorylation of a protein on the tyrosine residue using adenosine triphosphate as a substrate. The activities of tyrosine kinases ...
tyrosine kinase inhibitors肿瘤关键词: 肿瘤 临床研究术语 肿瘤基础研究 词汇介绍 拓展阅读解析 Tyrosine 英/'taɪrəsiːn/ 美/'taɪrəsɪn/ 释 义 n. [生化] 酪氨酸 例 句 Tyrosine: One of the amino acids, not essential for humans unless they have the hereditary disorder ...
4.4.1Tyrosine kinase inhibitors As described below,Stat3can be targeted at one or more steps in tumor progression. Specifically,tyrosine kinase inhibitorscan reducetyrosine phosphorylationof Stat3 and receptor complexes. The most common tyrosine kinase inhibitors that inhibit Stat3 activity are AG-490 and...
Other targeted agents that have been evaluated in phase 2 clinical trials for the treatment of hepatocellular carcinoma include tyrosine kinase inhibitors of the epidermal growth factor receptor … Josep M. Llovet et al., The New England Journal of MedicineDictionary...
Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding kinases from phosphorylating tyrosine residues of their substrates and then bl
Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer The success of tyrosine kinase inhibitors (TKIs) in select patients with non-small-cell lung cancer (NSCLC) has transformed management of the disease, plac......
Tyrosine kinase inhibitors 专利名称：Tyrosine kinase inhibitors 发明人：B. Wesley Trotter 申请号：US10510610 申请日：20030408 公开号：US07371754B2 公开日：20080513 专利内容由知识产权出版社提供 摘要：The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating ...
ActivatingandresistancemutationsofEGFRinnon-small-cell lungcancer:roleinclinicalresponsetoEGFRtyrosinekinase inhibitors AFGazdar HamonCenterforTherapeuticOncologyResearchandDepartmentofPathology,Universityof TexasSouthwesternMedicalCenter,Dallas,Texas,USA Abstract Theepidermalgrowthfactorreceptortyrosinekinaseinhibitors(EGFR...
The clinical benefit of tyrosine kinase inhibitors (TKIs)-based systemic therapy for advanced hepatocellular carcinoma (HCC) is limited due to drug resistance. Here, we uncover that lipid metabolism reprogramming mediated by unconventional prefoldin RPB5 interactor (URI) endows HCC with resistance to TK...
kinase and, subsequently, its downstream signaling, conferring oncogenic properties [32,36,37]. Numerous large international clinical trials have now shown that patients whose tumors harbor activating somaticEGFRTKD mutations are uniquely sensitive to treatment with EGFR tyrosine kinase inhibitors (TKIs) ...